Bong Soo Cha
Overview
Explore the profile of Bong Soo Cha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
3089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Ko S, Kim J, Kim K, Moon J, Kim N, et al.
Diabetes Metab J
. 2025 Jan;
49(1):24-33.
PMID: 39828976
Backgruound: This study aimed to investigate the prevalence, management, and comorbidities of diabetes mellitus among Korean adults. Methods: Data from the Korea National Health and Nutrition Examination Survey (2019-2022) were...
2.
Lee B, Lee Y, Park C, Rhee E, Lee W, Kim N, et al.
Diabetes Metab J
. 2020 May;
44(3):382-401.
PMID: 32431115
This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up...
3.
Lee M, Kim S, Watkins E, Moon M, Rhee S, Frias J, et al.
J Diabetes Complications
. 2020 Feb;
34(5):107555.
PMID: 32019723
Aim: MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel oral insulin sensitizer with its effects mediated by selective activation of...
4.
Lee Y, Cho Y, Lee B, Park C, Lee D, Cha B, et al.
Diabetes Metab J
. 2019 Nov;
43(5):731.
PMID: 31694085
This corrects the article on p. 31 in vol. 43, PMID: 30793550.
5.
Seo D, Kang S, Lee Y, Ha J, Park J, Lee B, et al.
Endocrinol Metab (Seoul)
. 2019 Oct;
34(3):282-290.
PMID: 31565881
Background: This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in patients with type 2 diabetes mellitus attending primary care clinics in Korea. Methods:...
6.
Hwang Y, Kim S, Hur K, Cha B, Kim I, Park T, et al.
J Korean Med Sci
. 2019 Apr;
34(15):e117.
PMID: 31001934
Background: Removal of uremic toxins such as indoxyl sulfate by AST-120 is known to improve renal function and delay the initiation of dialysis in patients with advanced chronic kidney disease....
7.
Kim K, Lee B, Kim Y, Lee D, Cha B, Park C
Diabetes Metab J
. 2019 Apr;
43(2):127-143.
PMID: 30993937
Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to...
8.
Lee H, Kim G, Choi Y, Huh B, Lee B, Kang E, et al.
Diabetes Metab J
. 2019 Mar;
44(2):267-276.
PMID: 30877708
Background: Impaired diastolic heart function has been observed in persons with non-alcoholic fatty liver disease (NAFLD) and/or with type 2 diabetes mellitus (T2DM). However, it is unclear whether NAFLD fibrotic...
9.
Seok H, Lee M, Shin E, Yun M, Lee Y, Moon J, et al.
Sci Rep
. 2019 Mar;
9(1):4414.
PMID: 30867485
Amyloid-β (Aβ) accumulation in the brain is a pathological feature of Alzheimer's disease (AD) and enhancing Aβ clearance is a potential therapeutic strategy. Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ)...
10.
Lee Y, Cho Y, Lee B, Park C, Lee D, Cha B, et al.
Diabetes Metab J
. 2019 Feb;
43(1):31-45.
PMID: 30793550
Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general...